Home > Oncology > ASCO 2020 > Genitourinary Cancer > Urothelial cancer: avelumab works as maintenance therapy

Urothelial cancer: avelumab works as maintenance therapy

Prof. Thomas Powles, Barts Cancer Institute, UK
ASCO 2020
Phase 3, JAVELIN Bladder 100
Featured video: Phase III interim analysis examining maintenance treatment with the immunotherapy avelumab after platinum-based first-line chemotherapy in advanced bladder cancer Prof. Thomas Powles (Barts Cancer Institute, UK) presented the results of the phase 3, multicentre, multinational, randomised, open-label, parallel-arm JAVELIN Bladder 100 study in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line, platinum-containing chemotherapy. The study met its primary endpoint by showing significantly longer overall survival with avelumab first-line maintenance versus control, both in the overall population and the PD-L1+ population [1]. First-line, platinum-based chemotherapy for advanced bladder cancer is charact...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on